An article published in the January issue of Immunotherapy1 noted that the U.S. incidence of melanoma is increasing rapidly, that current therapies are inadequate and toxic, and that melanoma is responsive to immune-stimulating drugs like Allovectin-7®. A Phase 3 trial evaluating the safety and efficacy of Allovectin-7® compared with standard chemotherapy is expected to complete final follow-ups later this year.
See this Amp at http://bit.ly/gbdF3t
No comments:
Post a Comment